Navigation Links
Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
Date:7/20/2009

CAMBRIDGE, Mass., July 20 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the second quarter and six months ended June 30, 2009. At June 30, 2009, Idenix's cash, cash equivalents and marketable securities totaled $51.7 million.

Business Highlights

  • Idenix announced today that it had successfully completed a proof-of-concept study of its lead HCV antiviral development program, IDX184, a novel once-daily liver-targeted nucleotide prodrug. This double-blind, placebo-controlled, monotherapy, dose-escalation study in HCV genotype-1-infected patients evaluated the safety and antiviral activity of IDX184. For more information on the results of this study, please see the related press release issued today by Idenix.
  • The company continued to advance its two preclinical HCV antiviral programs. Idenix is finalizing IND- or CTA-enabling preclinical studies for IDX375, a non-nucleoside polymerase inhibitor, and is preparing documentation to support initial regulatory filings. The company has synthesized the first kilogram of its lead protease inhibitor drug candidate and has initiated 28-day chronic toxicology studies in two species to support regulatory applications.
  • Finally, during the quarter, Idenix streamlined operations with the closure of its screening facility in Cagliari, Italy. This activity is now being performed at the company's laboratory in Cambridge, Massachusetts. As a result, Idenix reduced its workforce by 18 employees and incurred a restructuring charge in the quarter of $1.5 million.

"Our focus this year has been on the advancement of our HCV discov
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
2. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
3. Idenix Pharmaceuticals Reports First Quarter Financial Results
4. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
5. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
6. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
7. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
8. Idenix to Host Conference Call Discussing Fourth Quarter 2008 Financial Results
9. Idenix Pharmaceuticals to Present at the JP Morgan 27th Annual Healthcare Conference
10. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
11. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Rhinebeck, NY (PRWEB) May 17, 2013 ... by Topical BioMedics, Inc., has been listed among ... 2013 in an initiative conducted by "U.S. News" ... product has earned the “No. 1 Pharmacists ... with 17 other national OTC brands, and is ...
(Date:5/17/2013)... news release is available in German . ... too well: with the naked eye, you can see which ... in the blur of branches through the telephoto lens for ... for researchers who are looking to study proteins, the active ... ETH Zurich,s Institute for Molecular Systems Biology, and her colleagues ...
(Date:5/17/2013)... 2013 New interactive learning ... thought leaders of the medical device industry at ... and expo, from June 18-20 in ... http://photos.prnewswire.com/prnh/20130517/613829 ) , These all-new ... professionals practical presentations and implementable solutions on the ...
(Date:5/17/2013)... , May 17, 2013  Insero Health, Inc., ... needs in epilepsy and related neurological disorders, is today ... its lead compound INS001 in patients with drug-resistant epilepsy.  ... and Device Trials (AED) Xll meeting by Dr. ... and Chairman of Insero,s Scientific Advisory Board.  In this ...
Breaking Biology Technology:Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2Proteome atlas for the tuberculosis pathogen 2Proteome atlas for the tuberculosis pathogen 3MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
... PURE Bioscience (OTC,Bulletin Board: PURE), creators of patented ... revolutionary new hard surface,disinfectant which kills Staph/MRSA as ... will present at the Biocom Investor Conference,on Thursday, ... Del Mar. Michael L.,Krall, CEO, will discuss the ...
... Pharmasset, Inc.,(Nasdaq: VRUS ) management will be presenting at the ... & Renshaw 9th Annual Healthcare Conference being ... in New York City. Schaefer Price, ... provide an overview of the company on Tuesday, ...
... EMERYVILLE, Calif., Oct. 26 Bionovo, Inc.,(Nasdaq: BNVI ) ... of 10,000,000 shares of common stock at a price to ... shares of common stock,at $3.50 per share at a price ... to the underwriters to purchase up to an additional 15% ...
Cached Biology Technology:PURE Bioscience to Present at Biocom Investors Conference 2PURE Bioscience to Present at Biocom Investors Conference 3PURE Bioscience to Present at Biocom Investors Conference 4Pharmasset to Present at Three Investor Conferences in November 2007 2Bionovo Announces the Pricing of Public Offering of Shares of Common Stock 2Bionovo Announces the Pricing of Public Offering of Shares of Common Stock 3
(Date:5/18/2013)... Research presented at Digestive Disease Week (DDW) explores ... and lifestyle. , Individuals suffering from Crohn,s ... fatigue and poor quality of life. These symptoms ... A randomized, double blind, placebo-controlled study found for ... to significant relief of these symptoms. , ...
(Date:5/17/2013)... noise of the South, but the night belongs to the ... heavy from the humidity and the sounds of wildlife. ... frogs, toads and salamanders, is the center of amphibian biodiversity ... the auditorium for their symphonic choruses, the scientists of the ... have front-row seats. , Amphibians, which rely on ...
(Date:5/17/2013)... of a group of proteins in the brain responsible ... new target that could increase cell survival. , The ... Biochemistry and published in the EMBO journal ... to new therapies for stroke and other brain diseases. ... team which identified a protein, known as SUMO, responsible ...
Breaking Biology News(10 mins):Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4SUMO wrestling cells reveal new protective mechanism target for stroke 2
... that confer an evolutionary advantage upon a species, such ... difficult to detect and even harder to reproduce in ... evolutionary biologists. In findings published online in the September ... from the U.S. Department of Energy,s Lawrence Berkeley National ...
... that may have contributed to the evolution of the uniquely ... or foot that allow humans to walk on two legs, ... Sept. 5, 2008. This study is the first to ... are switches near genes in the human genome. ...
... have joined forces to develop a world-first,computerised system ... birth with greater accuracy., The University of Melbourne, ... combining,expertise in medical research, engineering and pathology to ... of a premature birth., About 17,000 pre-term births ...
Cached Biology News:Thumbs up -- a tiny ancestral remnant lends developmental edge to humans 2Thumbs up -- a tiny ancestral remnant lends developmental edge to humans 3Gene enhancer in evolution of human opposable thumb 2Gene enhancer in evolution of human opposable thumb 3World-first to predict premature births 2
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
Goat polyclonal to PPP2R5D Immunogen: Peptide with sequence KRAEEFLTASQEAL, from C Terminus of the protein sequence according to NP_006236...
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Mouse monoclonal [LH8] to Cytokeratin 5 + 14 ( Abpromise for all tested applications). entrezGeneID: 3852 SwissProtID: P02533...
Biology Products: